Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 18 2022 - 07:30AM
Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company
developing tumor-selective immuno-oncology therapies for people
living with cancer, today announced that Marty Huber, M.D.,
president of research and development and chief medical officer,
will present at the H.C. Wainwright Global Investment Conference on
Wednesday, May 25, 2022, at 2:30 p.m. ET.
A live webcast will be available in the Investors
and Media section of the Xilio Therapeutics’ website at
https://ir.xiliotx.com. A replay of the webcast will be archived on
Xilio Therapeutics’ website for 30 days following the
presentation.
About Xilio TherapeuticsXilio
Therapeutics is a clinical-stage biotechnology company focused on
harnessing the immune system to achieve deep and durable clinical
responses to improve the lives of patients with cancer. The company
is using its proprietary geographically precise solutions (GPS)
platform to rapidly engineer novel molecules, including cytokines
and other biologics, that are designed to optimize their
therapeutic index. These molecules are designed to localize
activity within the tumor microenvironment without systemic effect,
resulting in the potential to achieve enhanced anti-tumor activity.
Xilio is building a pipeline of wholly owned, tumor-selective,
GPS-enabled cytokine and checkpoint inhibitor product candidates,
including its clinical-stage programs, XTX101, a tumor-selective
anti-CTLA-4 monoclonal antibody, and XTX202, a tumor-selective
IL-2, as well as its earlier pipeline, including XTX301, a
tumor-selective IL-12. For more information, please
visit www.xiliotx.com and follow us on
Twitter (@xiliotx) and LinkedIn (Xilio Therapeutics,
Inc.).
For Investor Inquiries:Sal
GiovineChief Financial Officerinvestors@xiliotx.com
For Media Inquiries: Julissa
VianaVice President, Corporate Communicationsmedia@xiliotx.com
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Mar 2023 to Mar 2024